Apoglyx, Respinor and RetinaRisk Announced as NLSInvest Rising Star Award Winners
Apoglyx, Respinor and RetinaRisk Announced as NLSInvest Rising Star Award Winners
Pressmeddelande
2021-04-20 08:01
Sigurbjörg Ásta Jónsdóttir, CEO of RetinaRisk (Iceland), Michael Rützler, CEO of Apoglyx (Sweden) and Trude Tingvoll, CEO of Respinor (Norway).
Over 150 Nordic companies applied to the launch of the first-ever Nordic Life Science Investment Day, NLSInvest. Following a long review of the applications by a pan-Nordic committee of industry leaders, 80 Rising Stars were ultimately selected to pitch to investors across three dedicated tracks: biotech/pharma, medtech/diagnostics and digital/e-health.
From the 80 Rising Stars, one company from each track was selected as the category winner. The three winners will be awarded a package prize of 15,000 DKK, two registrations to NLSDays 2022, and one company presentation at the 2022 conference. This year, the